126 related articles for article (PubMed ID: 28127047)
1. Oncogenes: Coping with stress.
Seton-Rogers S
Nat Rev Cancer; 2017 Jan; 17(2):76-77. PubMed ID: 28127047
[No Abstract] [Full Text] [Related]
2. Mutant KRAS Enhances Tumor Cell Fitness by Upregulating Stress Granules.
Grabocka E; Bar-Sagi D
Cell; 2016 Dec; 167(7):1803-1813.e12. PubMed ID: 27984728
[TBL] [Abstract][Full Text] [Related]
3. Evaluating Stress Granules in Pancreatic Cancer In Vitro and In Vivo.
Sim E; Irollo E; Grabocka E
Methods Mol Biol; 2019; 1882():183-195. PubMed ID: 30378055
[TBL] [Abstract][Full Text] [Related]
4. Prognostic and predictive biomarkers in nonmetastatic colorectal cancers.
Haddad FG; Eid R; Kourie HR; Barouky E; Ghosn M
Future Oncol; 2018 Sep; 14(21):2097-2102. PubMed ID: 30101612
[No Abstract] [Full Text] [Related]
5. Metabolic Adaptation to Nutritional Stress in Human Colorectal Cancer.
Miyo M; Konno M; Nishida N; Sueda T; Noguchi K; Matsui H; Colvin H; Kawamoto K; Koseki J; Haraguchi N; Nishimura J; Hata T; Gotoh N; Matsuda F; Satoh T; Mizushima T; Shimizu H; Doki Y; Mori M; Ishii H
Sci Rep; 2016 Dec; 6():38415. PubMed ID: 27924922
[TBL] [Abstract][Full Text] [Related]
6. Identification of key pathways and genes in mutant KRAS colorectal cancer by integrated bioinformatics analysis.
Zhang H; Zhang X; Chen X; Zhang W; Xian J; Zhou X; Yang J; Wang J
Acta Biochim Biophys Sin (Shanghai); 2018 Jun; 50(6):615-617. PubMed ID: 29688256
[No Abstract] [Full Text] [Related]
7. The Moment that KRAS Mutation Started to Evolve into Precision Medicine in Metastatic Colorectal Cancer.
Ushijima T; Yoshino T
Cancer Res; 2016 Nov; 76(22):6443-6444. PubMed ID: 28148677
[No Abstract] [Full Text] [Related]
8. KY1022, a small molecule destabilizing Ras via targeting the Wnt/β-catenin pathway, inhibits development of metastatic colorectal cancer.
Cho YH; Cha PH; Kaduwal S; Park JC; Lee SK; Yoon JS; Shin W; Kim H; Ro EJ; Koo KH; Park KS; Han G; Choi KY
Oncotarget; 2016 Dec; 7(49):81727-81740. PubMed ID: 27835580
[TBL] [Abstract][Full Text] [Related]
9. Higher metastatic efficiency of KRas G12V than KRas G13D in a colorectal cancer model.
Alamo P; Gallardo A; Di Nicolantonio F; Pavón MA; Casanova I; Trias M; Mangues MA; Lopez-Pousa A; Villaverde A; Vázquez E; Bardelli A; Céspedes MV; Mangues R
FASEB J; 2015 Feb; 29(2):464-76. PubMed ID: 25359494
[TBL] [Abstract][Full Text] [Related]
10. Targeting KRAS in metastatic colorectal cancer: current strategies and emerging opportunities.
Porru M; Pompili L; Caruso C; Biroccio A; Leonetti C
J Exp Clin Cancer Res; 2018 Mar; 37(1):57. PubMed ID: 29534749
[TBL] [Abstract][Full Text] [Related]
11. Detection of Mutant RAS Subpopulations in Colorectal Cancer Patients.
Banda M
EBioMedicine; 2015 Apr; 2(4):280-1. PubMed ID: 26137569
[No Abstract] [Full Text] [Related]
12. Clinical validation of colorectal cancer biomarkers identified from bioinformatics analysis of public expression data.
Jung Y; Lee S; Choi HS; Kim SN; Lee E; Shin Y; Seo J; Kim B; Jung Y; Kim WK; Chun HK; Lee WY; Kim J
Clin Cancer Res; 2011 Feb; 17(4):700-9. PubMed ID: 21304002
[TBL] [Abstract][Full Text] [Related]
13. [Ras-oncogene detection in feces of patients with colorectal tumors].
Swinkels DW; de Kok J; van Muijen GN; Willems JL
Ned Tijdschr Geneeskd; 1996 Mar; 140(9):510-1. PubMed ID: 8628444
[No Abstract] [Full Text] [Related]
14. Pro-survival responses to the dual inhibition of anti-apoptotic Bcl-2 family proteins and mTOR-mediated signaling in hypoxic colorectal carcinoma cells.
Risberg K; Redalen KR; Sønstevold L; Bjørnetrø T; Sølvernes J; Ree AH
BMC Cancer; 2016 Jul; 16():531. PubMed ID: 27461218
[TBL] [Abstract][Full Text] [Related]
15. Frequency and impact of KRAS mutation in early onset colorectal cancer.
Perea J; Arriba M; Rodríguez Y; Rueda D; García JL; Pérez J; González-Sarmiento R; Urioste M
Hum Pathol; 2017 Mar; 61():221-222. PubMed ID: 27816716
[No Abstract] [Full Text] [Related]
16. Relationships among
Wan XB; Wang AQ; Cao J; Dong ZC; Li N; Yang S; Sun MM; Li Z; Luo SX
World J Gastroenterol; 2019 Feb; 25(7):808-823. PubMed ID: 30809081
[TBL] [Abstract][Full Text] [Related]
17. DNA profiling of tumor buds in colorectal cancer indicates that they have the same mutation profile as the tumor from which they derive.
Centeno I; Paasinen Sohns A; Flury M; Galván JA; Zahnd S; Koelzer VH; Sokol L; Dawson HE; Lugli A; Cathomas G; Zlobec I
Virchows Arch; 2017 Mar; 470(3):341-346. PubMed ID: 28130698
[No Abstract] [Full Text] [Related]
18. A novel resveratrol derivative selectively inhibits the proliferation of colorectal cancer cells with KRAS mutation.
Okamoto H; Matsukawa T; Doi S; Tsunoda T; Sawata Y; Naemura M; Ohnuki K; Shirasawa S; Kotake Y
Mol Cell Biochem; 2018 May; 442(1-2):39-45. PubMed ID: 28936721
[TBL] [Abstract][Full Text] [Related]
19. SLC25A22 Promotes Proliferation and Survival of Colorectal Cancer Cells With KRAS Mutations and Xenograft Tumor Progression in Mice via Intracellular Synthesis of Aspartate.
Wong CC; Qian Y; Li X; Xu J; Kang W; Tong JH; To KF; Jin Y; Li W; Chen H; Go MY; Wu JL; Cheng KW; Ng SS; Sung JJ; Cai Z; Yu J
Gastroenterology; 2016 Nov; 151(5):945-960.e6. PubMed ID: 27451147
[TBL] [Abstract][Full Text] [Related]
20. KRAS and BRAF mutation status in patients with sporadic colorectal cancer: data from two different Mediterranean countries.
Symvoulakis EK; Zaravinos A; Zoras O; Spandidos DA
Int J Biol Markers; 2011; 26(4):276-7. PubMed ID: 22139644
[No Abstract] [Full Text] [Related]
[Next] [New Search]
